No Data
No Data
Dian Diagnostics Group Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
Dian Diagnostics Group: Half-year report for the year 2024.
Dian Diagnostics Group: Summary of Half-Year Report in 2024.
Dian Diagnostics Group (300244.SZ): Net income for the first half of the year was 71.7468 million yuan, a year-on-year decrease of 84.17%.
Dian Diagnostics Group (300244.SZ) announced its semi-annual report for 2024, with total operating revenue of 6.218 billion yuan, a year-on-year decrease of 9.12%; net income attributable to shareholders of the listed company is 71.7468 million yuan, a year-on-year decrease of 84.17%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses is 75.2674 million yuan, a year-on-year decrease of 77.34%; basic earnings per share of 0.1153 yuan.
Dian Diagnostics GroupLtd (SZSE:300244) Sheds CN¥378m, Company Earnings and Investor Returns Have Been Trending Downwards for Past Three Years
Dian Diagnostics Group (300244.SZ) has PCR testing reagents and possesses detection technology for pneumonia.
Dian Diagnostics Group (300244.SZ) stated on the investor interaction platform on August 14th that the company has PCR detection reagents and possess the technology to detect pneumonia.
No Data